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DETECTION OF GENES INFLUCING CHRONIC AND MENDELIAN DISEASE VIA
LOSS-OF-FUNCTION VARIATION

Alexander Hung Li, M.S.

Advisory Professor: Eric Boerwinkle, Ph.D.

A typical human exome harbors dozens of loss-of-function (LOF) variants predicted to
severely disrupt or abolish gene function. These variants are enriched at the extremely rare end
of the allele frequency spectrum (< 0.1%), suggesting purifying selection against these sites.
However, most previous population-based sequencing studies have not included analysis of
genotype-phenotype relationships with LOF variants. Thus, the contribution of LOF variation
to health and disease within the general population remains largely uncharacterized.
Using whole exome sequence from 8,554 participants in the Atherosclerosis Risk in
Communities (ARIC) study, we explored the impact of LOF variation on a broad spectrum of
human phenotypes. First, we selected 20 common chronic disease risk factor phenotypes and
performed gene-based association tests. Analysis of this sample verified two relationships in
well-studied genes (PCSK9 and APOC3) and identified eight new loci. Novel relationships
included elevated fasting glucose in heterozygous carriers of LOF variation in TXNDC5, which
encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of
C1QTNF8 on serum magnesium levels. Next, we explored the effect of LOF variation on 308
small molecular metabolites, observing 8 significant genotype-phenotype associations. We
highlight the relationship between serum histidine and HAL, a gene essential to histidine
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catabolism, demonstrating the biologically interpretability of associations with molecular
metabolite targets. Finally, we explore the impact of LOF variation on a rare birth defect by
comparing sequence from 342 unrelated left ventricular outflow tract obstruction (LVOTO)
cases to ARIC sequence, identifying genes harboring case-exclusive LOF mutations.
Comparison to an a priori list of cardiac candidate genes revealed 28 genes potentially related to
LVOTO, including 22 not previously associated with a human disorder. Genotype validation in
these samples revealed diverse inheritance patterns, including 9 confirmed de novo variants
(ACVR1, JARID2, KMT2D, NF1, NR2F2, PLRG1, SMURF1, TBX20, and ZEB2).
The analytical strategy presented here highlights the role of biologically-informed
annotation on large-scale human genetic studies. The genes identified by these methods may
have applications in disease prediction and drug development, and future genome studies will
continue to refine our understanding of the scope of genetic variation affecting human health
and disease.
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Chapter 1: Introduction

1

Genetics, health and disease
Genomic information is emerging as a valuable addition to traditional health care and an
essential component of the National Institutes of Health’s precision medicine initiative1.
Knowing and understanding the content of an individual’s genome can inform a personalized
disease risk evaluation, since one’s DNA sequence is generally stable throughout a lifetime,
with the exception of somatic mutation and epigenetic modifications. For example, the content
of a genome may serve as biomarkers for late-onset conditions such as Alzheimer’s disease2,
common chronic conditions such as coronary artery disease3, or sensitivity to the anticoagulant
warfarin4. The genetic profile of an individual can be used to develop individualized
management strategies, such as informing clinicians which drugs may be most effective for
patients5. At the rare end of the disease spectrum, gene sequencing has also been used to
identify specific individuals having increased risk to develop clinical disease, especially when
informed by family history for a Mendelian disorder6.
Genetic studies may also point to attractive drug targets, especially when associated with
a beneficial health effect. For example, six pharmaceutical companies are actively developing
PCSK9 inhibitors7, two of which have entered phase III clinical trials, showing great promise
for lowering lipids and preventing major cardiovascular events8,9. The common paradigm of
these drugs is to downregulate levels of single gene product within a patient. Recent studies
have suggested that other genes, such as APOC310, may also make suitable targets for similar
drugs which act via a downregulation pathways to achieve a protective cardiovascular effect.
It is therefore of great interest to both clinicians and pharmaceutical companies to
understand the major genes that contribute to human health. This demand drives researchers to
discover novel associations and understand the contribution of these individual genes to human
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phenotypes. Next generation sequencing technology, especially whole-exome sequencing, has
emerged as a powerful and efficient tool to capture gene sequence which is a crucial step in this
discovery process.
Sequencing platforms for gene discovery
Whole exome sequencing (WES) has emerged as a cost-effective platform suitable for
both clinical diagnoses and research discovery. Over a dozen companies offer commercial
whole exome sequencing services (https://www.scienceexchange.com/services/whole-exomeseq) with costs ranging from$445 to $1,535 per sample. Per-sample costs within highthroughput sequencing centers may be even lower. Another advantage of WES is the ability to
capture sequence variation from across the allelic frequency spectrum, from common to rare or
even private sites. This contrasts with less expensive chip-based genotyping for gene discovery,
which may only provide information in a limited allele frequency spectrum or a slice of the
human genome (eg, loci previously characterized such as those ascertained by GWAS). These
chip-based platforms also target known variant sites and thus cannot be used for novel variant
discovery, an important aspect as we focus more on ethnically-diverse or isolated populations.
Additionally, the near-comprehensive gene coverage provided by WES is an advantage over
targeted sequencing methods, since these methods rely on a priori selection of gene candidates
which limits the potential for novel discovery. Finally, while whole genome sequencing
provides both comprehensive coverage and high-resolution detection of mutations, this platform
also has disadvantages compared to WES. For many applications whole genome sequence data
remains cost-prohibitive to generate and store. In addition, the interpretation of intergenic
genomic regions remains a challenge in the context of human disease studies, whereas the
sequence of exons is more readily interpretable
3

Within limits, exonic variants can be interpreted in the context of established molecular
biology paradigms. WES reliably ascertains and genotypes both single-nucleotide substitutions
and small insertions/deletions (up to 50bp) within the protein-encoding regions of genes. Since
these variants are in the exons of genes, the functional effects on mRNA splicing and protein
translation are predictable. A number of tools exist to predict the effect of protein-altering
nucleotide substitutions (e.g. Polyphen211, SIFT12), incorporating information from sequence
conservation, local amino acid context, and predicted protein structures that arise from these
sequence changes. However, there is no single consensus on which method performs best at
predicting pathogenicity, and there is poor correlation between the results of these tools13.
Given the difficulties of predicting the pathogenicity of protein-altering variation, we decided to
prioritize other functional classes of human variation.
Loss-of-function mechanism
Loss-of-function (LOF) variants are sequence changes that are predicted to severely disrupt
or even completely prevent the formation of protein from gene templates. True LOF variants
should be contrasted to predicted hypomorphs, which may influence function by changes in
amino acid context rather than overall gene levels. Several functional categories of LOF
variation exist: premature stop, splice, and frameshift indel. These diverse functional categories
of mutation converge on their potential to introduce premature stop (nonsense) signals into
mRNA transcripts, which are targeted for degradation by highly conserved molecular
pathways14.
The various types of LOF variants can all trigger specific reactions from eukaryotic mRNA
surveillance mechanisms, specifically the nonsense-mediated mRNA decay pathway (NMD).
This pathway monitors gene expression and identifies transcripts containing premature
4

termination codons. During normal transcription in the nucleus of cells, introns are spliced out
and adjacent exons are joined into a single contiguous mRNA transcript. Exon-junction
complex (EJC) factors contribute to this process and remain bound to the mature mRNA
transcript as it is exported into the cytoplasm, marking the junction where two exons have been
joined15 (Figure 1.1a). Since a transcript is expected to only contain one stop codon to indicate
the end of protein translation, no EJC factors should be bound to the transcript downstream of
this termination signal. The mammalian NMD pathway consists of core machinery which
interacts with EJC factors16. When DNA mutations alter gene sequence to encode for premature
stop codons in the non-terminal gene exon, mRNA-bound EJC factors will be detected
downstream of these termination signals. The presence of these aberrant EJC complexes factors
act as a “second signal” (ie, extra stop codon) when mRNA is proofread during translation
which destabilize the transcript and elicit NMD17 (Figure 1.1b).
LOF variants predicted to trigger NMD can be detected and annotated within WES data.
Single nucleotide substitutions giving rise to premature stop codons can be directly annotated,
and are likely to trigger NMD if they are not in the terminal exon18. Similarly, frameshift indels
disrupting the 3-bp reading frame of all downstream codons often lead to low levels of gene
transcript19. Mutations disrupting essential splice motifs also trigger NMD, as errors in RNA
splicing often trigger NMD20. However, certain protein-coding genes may resist NMD, and
these must be taken into account during variant annotation. As expected, intronless genes are
resistant to EJC-mediated NMD21,22. Human beta-globin genes may escape NMD if a

5

Figure 1.1: Loss-of-Function
Function mechanism. Figure depicts the role of the EJC in a form of NMD
surveillance by which mRNA transcripts with premature stop codons are targets for degradation
by the cell. (A) Normal mRNA transcript which will be translated into protein, with a single
stop signal in the terminal exon. (B) Mutant mRNA transcript with LOF mutation (exon 2 and
exon 3), whereby the premature stop signal redirects this transcript to be degraded before
protein translation can occur. Image adapted from eLife 2014;3:e04300.
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premature stop signal arises very early in the transcript (within exon 1) and sequences allowing
re-initiation of translation reside at a downstream alternate start codon23.
Loss of Function variation in health and disease
The prevalence of LOF variation in general human populations has been described24. A
normal, healthy individual carries approximately 100 genes with variants predicted to have an
LOF effect (20 homozygous), with varying rates between ancestry groups (Figure 1.2).
Interestingly, these variants are enriched at the rare end of the population allele frequency
spectrum, suggesting selection against these sites24. The relative frequency of these sites across
genes can also provide insights into genetic architecture of human traits. For example, at the
population level, these sites are observed less frequently in genes known to cause autosomal
dominant Mendelian disorders25.
LOF mutations have also been implicated in human disease. In studies of rare Mendelian
disorders, disease pathology is generally attributed to a single rare (often unique) mutation
within a patient. Human mutation databases such as the Human Gene Mutation Database
(HGMD, http://www.hgmd.cf.ac.uk/) and ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/)
curate and catalog the specific mutations reported to cause rare disease. HGMD (2015.1)
describes 17,562 premature stop variants and 34,466 frameshift indels classified as diseasecausing mutations. Similarly, the NCBI ClinVar database includes description of 10,222
pathogenic LOF variants (4,892 premature stop, 1,767 splice, and 3,561 frameshift indel).
The role of LOF variation in common disease has been less extensively studied, but early
results have been encouraging. African American individuals with variation introducing
premature stop codons in PCSK9 present lower serum LDL cholesterol and decreased risk for
coronary heart disease than non-LOF individuals26. These results have sparked an interest in
7

Figure 1.2: Prevalence of Loss
Loss-of-Function variation in human populations. This figure depicts
the average number of function variation per sample, representing three different ancestry
groups from the 1000 genomes project. Image adapted from the 1000 genomes project24.
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PCSK9 as a drug target to lower cholesterol, with multiple drugs targeting this gene in
development. Similarly, individuals with LOF variation in APOC3, including splice and
premature stop, present lower serum triglycerides a reduced risk for coronary heart disease
compared to others individuals without similar variation in this gene10.
Despite these encouraging results in population-based studies and the ubiquitous frequency
of these variants within human populations, the effect of LOF variation on human phenotypes in
the general population remains poorly characterized. In addition, novel LOF variants that
contribute to rare disease are an important tool for novel gene discovery. Therefore, we set out
to characterize the effect of LOF variation on broad spectrum of human phenotypes including
common complex disease biomarkers, small molecule metabolite levels, and cohorts of patients
with rare Mendelian disorders.

9

Chapter 2: Common chronic disease biomarkers

This chapter is based on: Li, A. H., Morrison, A. C., Kovar, C., Cupples, L. A., Brody, J. a,
Polfus, L. M., Yu, B., Metcalf, G., Muzny, D., Veerereghavan, N., Liu, X., Lumley, T., Mosley,
T. H., Gibbs, R. A., Boerwinkle, E. (2015). Analysis of loss-of-function variants and 20 risk
factor phenotypes in 8,554 individuals identifies loci influencing chronic disease. Nature
genetics, 47(6), 640–642. doi:10.1038/ng.3270.

Since 2003, ownership of copyright in in original research articles remains with the Authors,
and provided that, when reproducing the Contribution or extracts from it, the Authors
acknowledge first and reference publication in the Journal, the Authors retain the following nonexclusive rights:

a. To reproduce the Contribution in whole or in part in any printed volume (book or thesis)
of which they are the author(s).
b. They and any academic institution where they work at the time may reproduce the
Contribution for the purpose of course teaching.
c. To reuse figures or tables created by them and contained in the Contribution in other
works created by them.
d. To post a copy of the Contribution as accepted for publication after peer review (in
Word or Tex format) on the Author's own web site, or the Author's institutional
repository, or the Author's funding body's archive, six months after publication of the
printed or online edition of the Journal, provided that they also link to the Journal article
on NPG's web site (eg through the DOI).
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Introduction
Investigations of genotype-phenotype associations leading to novel gene discovery have
traditionally been facilitated by focusing on the most severe or earliest age of onset cases4. An
alternative approach would be to identify variants with the most severe functional effects in a
sample of deeply-phenotyped individuals, and then investigate the role of these variants in
health and disease. To test this approach, we sequenced the exomes of 8,554 individuals who
have been measured for many phenotypes related to common chronic diseases, such as diabetes
and coronary heart disease. We annotated predicted loss-of-function (LOF) variants in these
individuals and investigated their impact on 20 chronic disease risk factor phenotypes. Genebased analyses identified and replicated 10 genetic loci associated with these measured traits.
These results demonstrate the importance of detailed biological annotation to inform large-scale
sequencing studies, and the utility of deeply-phenotyped cohort studies to further elucidate the
genetic architecture of human health and disease.
Whole exome sequencing was performed on 2,836 African-American and 5,718 EuropeanAmerican individuals from the Atherosclerosis Risk in Communities (ARIC) study (Table 2.1).
Ninety percent of target sites were covered at 20x or greater (mean depth 110.1 per sample),
revealing 1,911,892 total single nucleotide variants (SNV) with an average Ti/Tv of 3.3 per
sample, and 38,219 small insertions and deletions (indels). Indel sizes ranged from -51 base
pairs (bp) to +27 bp, with a mode of -1 bp. We defined LOF variation as sequence changes
predicted to abolish protein formation from all RefSeq isoforms for a given gene and identified
a total of 36,561 candidate LOF sites (13,783 frameshift indels, 8,772 splice, 14,006 premature
stop, Table 2.2) in 11,260 protein-coding genes. Not surprisingly7, LOF variants were enriched
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Table 2.1: Overview of individuals included in this study. Baseline characteristics of African
American (AA) and European American (EA) participants from the ARIC cohort are shown,
including the total number of individuals undergoing whole exome sequence, age at enrollment,
gender distribution and body mass index (BMI).

Discovery

Replication

Characteristic

AA

EA

AA

EA

Individuals

1,418

2,859

1,418

2,859

Age

53.06 + 5.75

54.29 + 5.68

53.3 + 5.81

54.47 + 5.65

Males (%)

505 (35.61%)

1,378 (48.19%)

520 (36.67%)

1,338 (46.79%)

BMI

29.87 + 6.28

26.89 + 4.71

29.71 + 6.31

26.88 + 4.74
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Table 2.2: Number of LOF sites in the study sample and per individual. This table describes
the total number of LOF sites observed, and the average number of heterozygous (homozygous
in parentheses) LOF sites per individual.

LOF sites

Average per individual

AA

EA

Combined

AA

EA

Stop

5,837

9,312

14,006

27.3 (2.1)

21.1 (2.2)

Splice

3,789

5,731

8,772

16.7 (1.9)

9.6 (1.8)

Frameshift

6,575

8,264

13,783

36.1 (4.4)

22.6 (3.1)

Total LOF

16,201

23,307

36,561

80.1(8.4)

53.3 (7.1)

13

in the very rare range of the site frequency spectrum (MAF < 0.1%) compared to other
functional categories (Figure 2.1).
LOF OP ratio
We next characterized the prevalence of LOF variation by gene. Because mutations may
arise more frequently in larger genes and codon usage influences the chance of premature stops,
we exhaustively simulated every single nucleotide substitution within each gene transcript to
determine the maximum number of potential LOF substitution sites within that gene, which we
then compared to the observed number of LOF sites within our sample (observed
number/potential number = OP ratio)11,7. Almost half the genes in our capture regions presented
no LOF alleles (n = 7,115, OP ratio = 0). The OP ratios of the remaining genes form a
distribution with a peak near 0.003 with a skewed right tail (Figure 2.2a), underscoring the role
of purifying selection against these sites. Genes known to influence human phenotypes in a
dominant manner8 present smaller average OP ratios (Figure 2.2b), while known recessive
disease genes7 have larger OP ratios (Figure 2.2c). The relationship between the OP ratio and
the effects of LOF variants on the 20 risk factor phenotypes analyzed here is complex. Clearly,
genes lacking LOF variants (i.e. OP ratio = 0) are not contributing to the analysis. Conversely,
genes that tolerate a large number of LOF variants and have a high OP ratio (e.g. OP ratio > 0.1)
did not significantly contribute to phenotypic variation. Genes contributing to the genetic
architecture of health and disease in the population are likely to be important, by virtue of
having an above average OP ratio, but not so critical such that LOF variants lead to debilitating
disease or are inconsistent with life. To this point, we observed that homologs of essential
mouse genes9 (lethal phenotypes) have smaller average OP ratios compared to non-essential
phenotype-changing genes (p < 10-6, Wilcoxon), and the latter have smaller OP ratios compared
14

Figure 2.1: Site frequency spectrum of four categories of exome variation.
The relative proportion of these functional categories is shown binned by allele frequency. LCP
= low-confidence
confidence or partial LOF criteria are described in the Methods Summary; Non-syn
Non
=
nonsynonymous; Syn = synonymous.
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Figure 2.2:: OP ratio trends across gene groups. (A) histogram of OP ratio for each gene; (B)
lower OP ratio in genes causing dominant disorders (n = 248) vs other genes (n = 16,435), (C)
higher OP ratio in genes causing recessive disorders(n = 652) vs other ((n
n = 16,031), (D) lower
OP ratio in human paralogs of essential mouse genes (Essential = embryonic lethal phenotype, n
= 2,356; Nonessential = non--lethal
lethal phenotype, n = 3,520; Other = no phenotype reported, n =
10,807). Panels for B, C and D are boxplots ddenoting
enoting the median value, hinges at the 25th and
75th percentile, and whiskers extending to 1.5x inter
inter-quartile range.
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to all other genes (p < 10-6, Wilcoxon) (Figure 2.2d). Genes with smaller OP ratios also tend to
be stably expressed in more tissues and interact with more proteins (Figure 2.3).

Phenotype associations
To detect associations between LOF variation and common chronic disease phenotypes, we
divided our sample into two non-overlapping discovery and replication groups each containing
4,277 individuals (Table 2.1, Table 2.3). Since LOF annotation enriches for variation with a
similar predicted functional effect, namely the reduction or abolishment of protein formation,
we grouped LOF variants by gene and performed a burden test for sites with MAF < 5% (T5
test)10. A summary of the most significant replicating results is shown in Table 2.4. As
expected, LOF variants in PCSK9 were associated with lower total cholesterol levels11, and LOF
variation in APOC3 were associated with lower triglyceride levels12. We observed 8 novel
relationships with compelling statistical evidence that replicated between the two samples
(Table 2.4). Except for PCSK9 and APOC3, the effects were in the direction thought to be
increasing risk of disease.
Highlighting two examples, nine individuals with LOF variation in Thioredoxin Domain
Containing 5 (TXNDC5) had elevated fasting blood glucose levels compared to non-LOF
individuals (Figure 2.4a), and this gene has recently been suggested as a candidate for type 1
diabetes(T1D) risk3. In follow-up analyses, we observed a weak association between TXNDC5
variation and fasting insulin levels within the ARIC study cohort (p = 0.047) (data not shown).
In addition, five European-American study participants had a LOF mutation in SEPT10 and
these individuals had significantly reduced lung function (ratio of forced expiratory volume to

17

Figure 2.3:: OP ratio trends across additional gene groups. (A) We selected the top 5% of
genes from the egenetics database expressed in the most tissues, denoted as “Universally“Universally
expressed” (n=834) which we compared to all other genes (n=15,849). (B) We selected the top
5% of genes from the ConsensusPathDB database with the most protein interactions (n=834)
which we compared to all other genes (n=15,849).
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Figure 2.4:: Distribution of phenotypes in LOF carriers. (A) Elevated fasting glucose in
TXNDC5 LOF heterozygotes (n = 9) compared to individuals with no LOF variation in this
gene (n = 8,545); (B) Elevated serum magnesium in C1QTNF8 homozygous individuals (n = 4)
compared
ompared to LOF heterozygotes (n = 62) and non
non-LOF
LOF samples (n = 8,488). Both panels are
boxplots denoting the median value, hinges at the 25th and 75th percentile, and whiskers
extending to 1.5x inter-quartile
quartile range.
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Table 2.3: List of phenotypes analyzed. This table describes with number of individuals (AA =
African American; EA = European American) who were measured for each trait within the
discovery and replication strata
Discovery

Replication

Category

Trait

Symbol

EA

AA

EA

AA

Electrolytes

Serum magnesium

Mg

2,858

1,369

2,859

1,377

Serum phosphorus

P

2,858

1,369

2,859

1,377

Serum calcium

Ca

2,858

1,369

2,859

1,377

Serum potassium

K

2,858

1,369

2,859

1,377

Serum sodium

Na

2,858

1,369

2,859

1,377

Aspartate transaminase

AST

2,315

934

2,306

926

Alanine aminotransferase

ALT

1,411

807

1,327

797

Gamma-glutamyl
transpeptidase
Diastolic blood pressure

GGT

1,413

807

1,329

797

DBP

2,857

1,417

2,859

1,418

Systolic blood pressure

SBP

2,858

1,417

2,859

1,418

Forced vital capacity

FVC

2,850

1,397

2,855

1,397

Forced expiratory volume/

FEV1FVC

2,850

1,397

2,852

1,396

Serum triglycerides

TRG

2,854

1,337

2,856

1,359

Total cholesterol

TCH

2,853

1,337

2,855

1,359

Fasting insulin

FI

2,784

1,273

2,804

1,284

Fasting glucose

FG

2,784

1,273

2,804

1,283

Creatinine

CRE

2,330

948

2,314

935

Uric acid

UA

2,858

1,369

2,859

1,377

White blood cell count

WBC

1,411

811

1,326

801

Lactate

LAC

2,855

1,351

2,848

1,364

Liver enzymes

Blood Pressure

Lung function

Fatty acids

Diabetes

Kidney

Other
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Table 2.4: Top gene-based phenotype associations which replicated. This table describes 10
significant associations which replicated and > 3 individuals contributed to the genotypephenotype association. “Genotype” denotes the heterozygous (“Het”) or homozygous (“Hom”)
state of LOF individuals. “LOF sites” (snv, indel) describes the number of variants included for
the T5 analyses. T5 betas were standardized (“Std Beta”) by calculating the ratio of beta over
the standard error. AA = African American; EA = European American; Disc = Discovery strata;
Rep = Replication strata; Total = Discovery + Replication pooled.

Genotype
Het

Trait
Creatinine

Fasting glucose
FEV1/FVC ratio

Homo

Gene

LOF Ethnicity
sites AA EA

T5 p-value
Disc.
–6

Rep.

Total

Std.
Beta

0.01

2.71x10–6

4.69

2 (1,1)

0

3

6.71x10

PLEKHG1 3 (1,2)

1

2

9.06x10–6

3.0x10–3

8.70x10–8

5.35

3 (2,1)

1

2

6.14x10–4

2.48x10–6

9.38x10–9

5.74

TXNDC5 7 (4,3)

6

3

6.82x10–4

5.75x10–5

5.62x10–7

5.00

5

–6

1.21x10

–4

3.07x10

–6

–4.67

5.52x10

–6

1.91x10

–6

4.76

LHCGR

GLIPR1
SEPT10

5 (1,4)

0

6.26x10

–3

Lactate

WDR62

3 (1,2)

3

0

8.0x10

Tot. cholesterol

PCSK9

6 (3,3)
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2

8.27x10–5

4.44x10–4

5.25x10–8

–5.44

Triglycerides

APOC3

4 (3,1)

13

24

1.25x10–9

1.38x10–8

7.98x10–17

–8.33

TIGIT

2 (1,1)

2

1

2.74x10–4

3.88x10–3

4.11x10–6

4.61

C1QTNF8 1 (1,0)

0

4

0.02

1.31x10–5

5.20x10–5

4.08

Magnesium
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the forced vital capacity, FEV/FVC, p=3.07 x 10-6). SEPT10 is contained with a known linkage
peak for nicotine dependence4, and three of the five LOF carriers were self-reported to be
former smokers.

Considering that LOF alleles may primarily influence phenotype in the homozygous state13,
we separately analyzed 1,156 homozygous LOF sites representing 921 genes. Similar genebased T5 tests were performed to compare the phenotype levels in LOF homozygotes to other
individuals within the sample. We observed one homozygous association which replicated
(Table 2.4). Four individuals were homozygous for LOF mutations in C1q and Tumor Necrosis
Factor Related Protein 8 (C1QTNF8) and these individuals had elevated serum magnesium
levels (Figure 2.4b). This diverse family of genes, including adiponectin, is linked to both
metabolism and inflammatory processes14, although this particular member is not wellcharacterized.
Discussion
We identified 10 LOF mutation-phenotype relationships that were both significant and
replicated, but it is important to more broadly consider the concept of replication in the context
of rare variant studies. In this study, 101 genotype-phenotype relationships with compelling
statistical evidence (p < 4.4x10-6) were exclusive to either the discovery or replication group; in
these cases, LOF mutations were only present in one or the other sample, but not both. These
"absent" replications are not directly supported nor discredited, as they represent chance absence
of the appropriate rare event (Figure 2.5).
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Figure 2.5:: LOF variants and genes carrying LOF variants with increasing sample size. For
each sample size n, we randomly chose n ARIC individuals and observed the number of LOF
variants and genes harboring tthem.
hem. This process was repeated 1,000 times to calculate the
average numbers of LOF variants and genes carrying LOF variants for sample size n.
n
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Identification of LOF variation influencing chronic disease risk factors represents a new and
diverse paradigm in genomic medicine. LOF variation in certain genes, such as TXNDC5, may
predispose individuals to develop disease. Further characterization of these risk loci will allow
researchers and clinicians to better understand the pathways and mechanisms underlying
disease risk, and to develop prevention strategies for at-risk patients as DNA sequencing moves
inevitably towards common clinical practice. LOF variation can also have a protective, risklowering effect on their carriers. When coupled with knowledge about lack of other adverse
effects, such LOF mutations may translate into novel drug targets. For example, LOF variants
in PCSK9 are associated with reduced LDL-cholesterol levels and incident coronary heart
disease, fueling a burgeoning and successful effort to identify PCSK9 inhibitors15.
Discovery of novel gene associations via exome sequencing has many challenges, and
represents a classic problem related to the signal-to-noise ratio. This study employed three ways
to increase signal in whole exome sequence analyses. First, by including biochemical measures
of risk factor levels, we optimize the size of a gene’s effect relative to the corresponding disease
endpoint. Second, the data presented here reinforces the need to have ethnic diversity in
sequence-based gene discovery studies because the sentinel signals may be race-specific. And
third, by careful annotation of the sequence motifs and variation, in this case by focusing on
LOF variation, we increase the likelihood of detecting a functional effect. As we make the
transition from whole exome sequencing to whole genome sequencing16 careful annotation of
variants with functional effect will become even more important and challenging.
Methods
Sample Ascertainment
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Whole exome sequence data was derived from 8,554 individuals (5,718 EA; 2,836 AA)
sampled from the Atherosclerosis Risk in Communities (ARIC) study cohort. Each ancestry
group was then randomly divided in half to create two non-overlapping and identically-sized
groups of 1,418 AA and 2,859 EA individuals for discovery and replication. EA individuals
were selected as part of a large cohort random sample or had extreme values for at least one of
the following phenotypes: age at menopause, electrocardiogram QT interval, fasting blood
glucose, fibrinogen level, renal function, Stamler-Kannel-like extremes of risk factors selected
by principal components, and waist-to-hip ratio. ARIC AA samples were randomly selected
within the ARIC cohort for whole exome sequencing. A detailed description of the ARIC study
is provided elsewhere24.

Phenotying
For these analyses, we selected heart/lung/blood phenotypes related to cardiovascular
outcomes that were (1) specifically not included in the sampling design to reduce potential bias
and (2) measured across the entire cohort to maximize sample size. The full set of phenotypes
included in these analyses is listed in Table 2.3. Serum magnesium (Mg) was measured using
the metallochromic dye, Calmagite. Phosphorus (P), calcium (Ca), and creatinine (CRE) levels
were measured using methods based on ammonium molybdate, o-cresolphthalein complexone,
and modified kinetic Jaffe-picric acid, respectively. Serum potassium (K) and sodium (Na)
levels were measured with a direct electrochemical technique. The liver enzymes, aspartate
transaminase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase
(GGT) were measured using standard methods. Blood pressure was measured using a
standardized Hawskley random-zero mercury column sphygmomanometer with participants in a
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sitting position after a resting period of 5 minutes. The size of the cuff was chosen according to
the arm circumference. Three sequential recordings for systolic (SBP) and diastolic blood
pressure (DBP) were obtained; the mean of the last two measurements was used in this analysis,
discarding the first reading. Forced vital capacity (FVC) and the ratio of forced expiratory
volume in one second (FEV1) to FVC were measured using a spirometer and the Pulmo-Screen
II software. Triglycerides (TRG) and total cholesterol (TCH) were measured after an overnight
fast using enzymatic methods. Fasting insulin (FI) was measured via radioimmunoassay.
Glucose (FG) was measured with the hexokinase method on individuals having fasted > 8 hours
prior to obtain fasting glucose. Uric acid (UA) was measured by the Uricase method. White
blood cell (WBC) count was determined by an automated particle counter. Lactate (LAC) was
measured using an enzymatic reaction that converts lactate to pyruvate.

Whole exome sequencing
DNA sequencing was performed on Illumina HiSeq instruments (San Diego, CA) after
exome capture with VChrome2.1 (NimbleGen, Inc., Madison, WI) using chemistry
recommended by the manufacturer. Sequence alignment and variant calling were performed
using the Mercury pipeline in the DNA Nexus41.

Variant calling and quality control
Mapping against Genome Reference Consortium Human Build 37 (GRCh37) was done
using Burrows-Wheeler Alignment (BWA)42 and allele calling and variant call file construction
was performed with the Atlas2 suite (Atlas-SNP and Atlas-Indel) to produce a variant call file
(VCF)43. The VCF includes filters for low-quality sites which were omitted from analyses,
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including low-quality single nucleotide variants with a SNP posterior probability less than 0.95,
total depth of coverage less than 10x, an allelic fraction < 0.1, 99% reads in a single direction
and homozygous reference alleles with < 6x coverage. Similar, but stricter filters were applied
to identify low-quality indels with the following differences: (1) minimum total depth < 60, (2)
allelic fraction < 0.2 for heterozygous variants (< 0.8 for homozygous variants) and (3) variant
reads < 30.

Validation
We validated a subset of LOF candidate genotypes using independent platforms with an
emphasis on indels. We used targeted sequencing methods (Sequenom and Sanger) and
observed a validation rate of 97.4% for SNV and 92.5% for LOF indel sites (Table 2.5).
This study took advantage of two opportunities to validate LOF variants detected by the
Illumina HiSeq instrument and the Mercury data processing pipeline. First, 2,649 SNV LOF
sites observed within our sample were also targeted on the Illumina exome chip44. Within this
overlap, 98% of genotypes were identical between these two platforms. Second, we selected 263
LOF genotypes (176 indel, 87 snv) to validate on independent platforms (Table 2.5). These
variants were a mixture of our top phenotype association results presented in Table 2.4 and
convenience sample of other sites, with oversampling of indels because of previous experience
with their validation rates. These genotypes represent 147 unique LOF sites (126 indel, 21
SNV). Validation genotypes were re-genotyped via both Sanger sequencing and a targeted
Sequenom panel. Twenty-four genotypes failed both assays. Concordant genotypes were
observed for 225 LOF genotypes (148 indel, 77 snv), and at least one platform was discordant
for 14 genotypes. Of note, none of the 14 discordant genotypes failed to validate on both
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Table 2.5: Summary of Sanger/Sequenom validation rate by LOF class. Validation procedures
are described in detail in the Methods Summary and Supplement IIb. “Selected genotypes” =
number of LOF HiSeq genotypes submitted for validation via Sanger/Sequenom; “Failed
genotypes” = no results from validation assay; “Remaining genotypes” = Submitted - Failed;
“Conflicting genotypes” = Sanger/Sequenom genotypes do not match HiSeq; “Validated
genotypes” = Sanger/Sequenom genotypes match HiSeq; “Validation Rate” = “Validated
genotypes” / “Remaining genotypes”.

Validation Status

SNP

INDEL

Total

Selected genotypes

87

176

263

Failed genotypes

8

16

24

Remaining genotypes

79

160

239

Conflicting genotypes

2

12

14

Validated genotypes

77

148

225

Validation Rate

0.974

0.925

0.941
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platforms and represent inconsistencies between the validation platforms. Thus, using
definitions that are common in the field, the observed validation rate for sites was 100%, and the
observed validation rate for genotypes was 94.1% (225/(263-24)). More specifically the
observed rate for genotypes was 97.4% for SNV and 92.5% for indel sites, and this may be a
conservative underestimate of the true validation rate of our Illumina HiSeq data.

Annotation
We defined loss-of-function variation as sequence changes predicted to trigger
nonsense-mediated decay of mRNA transcripts derived from all isoforms of a given gene.
Thus, the basic annotation29 categories of variation analyzed were premature stop codons,
essential splice site disrupting, and indels predicted to disrupting the downstream reading frame.
We further enriched for variants likely to abolish protein formation by identifying and excluding
(1) stop-gain mutations occurring in the terminal gene exon, and (2) LOF candidates which did
not map to chromosomal coordinates used by all gene isoforms for a given gene (“lowconfidence-partial” (LCP)). Finally, we excluded candidate LOF sites with a MAF > 0.5 and
genes lacking introns or designated non-protein-coding by RefSeq.
We used resampling methods to determine the relationship between sample size and
LOF variant ascertainment. For each sample size n, we randomly chose n samples from the
total samples and counted both the number of LOF variants observed and the number of genes
carrying LOF variants. We repeated the process 1,000 times and calculated the average numbers
of LOF variants and genes carrying LOF variants for sample size n. Table 2.5 shows the
average numbers of LOF variants and genes carrying LOF variants with increasing sample size.
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Genotype-phenotype association
A gene-based burden test (T5)32 was used to evaluate the association between
aggregated rare LOF variants and phenotypes. We chose to employ this test due its
interpretable detection of unidirectional phenotype mean shifts between LOF carriers and noncarriers. The following phenotype transformations were performed for T5 analyses: ALT, AST,
CRE, FI, and LAC underwent natural log transformation; FEV1FVC, GGT and MG underwent
power transformation; CA was corrected using the following formula: total calcium (mmol/l) +
([40 - serum albumin (g/dl)] * 0.025). TCH was adjusted (TCH/0.8) only among statin users;
measured SBP and DBP were respectively adjusted by +15 mmHg and +10 mmHg for
individuals taking anti-hypertensive medication; all other traits did not require transformation.
T5 tests were implemented using the SeqMeta package available in Cran R (http://cran.rproject.org/web/packages/seqMeta/), and only associations that were 1) independently detected
in both sample strata, 2) persisted with the inclusion of all samples, and 3) driven by > 3
individuals are presented in Table 2.4. Allele frequencies were calculated separately for each
ancestry group and only variants with an observed MAF < 5% were included in ancestryspecific analyses. Based on a Bonferroni correction procedure for the number of genes in our
sample presenting LOF variation (n = 11,260), a p-value of 4.4x10-6 was considered statistically
significant. Similarly, a p-value of 5.42x10-5 was considered significant for associations driven
by homozygous individuals, adjusting for the number of genes presenting homozygous LOF
genotypes (n=921). Quantile-quantile plots of all T5 p-values are provided in Figure 2.6 and
Figure 2.7.
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OP Ratio
We developed the OP ratio (“Observed” /”Potential”) as a gene-based metric to quantify
LOF variation while accounting for transcript size, and as a useful tool to compare the rate of
LOF variation in different gene groups. This metric is the ratio of the number of observed LOF
sites in a gene to the number of possible LOF sites that could arise due to single-nucleotide
substitutions. We compared the OP ratio to other measures of gene variability. We used the
egenetics database30 to rank all genes by the number of tissues where they are stably expressed,
calling the top 5% of this list "universally expressed". On average, we observe a smaller OP
ratio within stably expressed genes compared to all others (Figure 2.3a). Similarly, we sorted
the genes according to the number of known protein interactions according to
ConsensusPathDB31, and categorized the top 5% of these genes as "highly-interacting genes".
This gene group also has a smaller OP ratio on average compared to other genes (Figure 2.3b).
We compared our OP ratio with the Residual Variation Intolerance Score (RVIS)32 for
15,053 genes having both OP ratio and RVIS available. RVIS is based on the ratio of common
non-synonymous and splicing-site SNPs to the total numbers of coding SNPs using the
ESP6500 dataset. Both the OP ratio and RVIS are designed to measure the gene tolerance of
damaging amino acid changes, but are different as to the way of measurement and the databases
they are based on. Both the Pearson’s correlation coefficient (0.204) and the Spearman’s rank
correlation coefficient (0.229) between the two scores are highly statistically significant (p ~=0),
although we do not see clear linear relationship between them (Figure 2.8).
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Figure 2.6: Quantile-quantile plots of p-values from T5 associations with 20 phenotypes. The
95% confidence intervals are depicted and each dot represents one gene. Phenotype symbols
are defined in Supplementary table 2.
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Figure 2.7: Quantile-quantile plots of p-values from T5 homozygous associations with 20
phenotypes. The 95% confidence intervals are depicted and each dot represents one gene.
Phenotype symbols are defined in Supplementary table 2.
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Figure 2.8: Relationship between OP ratio and RVIS for 15,053 genes. The y-axis
y
depicts the
OP ratio and the x-axis
axis shows RVIS scores as described by Petrovski et al48. Each circle
represents one gene.
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Chapter 3: Metabolite intermediate phenotypes
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Introduction
Complex molecular interactions between the products of gene function and external
environmental influences underlie and culminate in the gross anatomic, metabolic, and
physiologic traits analyzed in the other chapters of this thesis (e.g., lung function, blood
pressure, cardiac birth defects, etc). Many of these molecular interactors are mediated by small
molecule metabolites, and the totality of these small molecules in a system is referred to as the
human metabolome.
Many features of the metabolome are appealing for genetic association studies. First,
metabolites may be directly encoded by genes or may function in close biological proximity to
gene products. For example, they can serve as substrates for enzymes that are directly encoded
by genes49. This proximity increases the interpretability of associations, and may also reduce
the possibility for confounding by interaction with networks of other small molecules. Next, the
metabolites may serve as biomarkers for disease prediction before the onset of clinically
recognized symptoms. For example, amino acid profiles within individuals have recently been
used to predict coronary artery disease50, myocardial infarction51, and other cardiovascular
outcomes52. Finally, metabolites are readily quantifiable. Recent technological advances allow
high-throughput quantification of these small molecules comprising the human metabolome.
Bioanalytical techniques emerging from advances in high-performance liquid-phase
chromatography (HP-LPC) allow for simultaneous measurement of hundreds of small
molecules within a single blood sample.
Metabolites have been studied at the population level through genome wide association
studies (GWAS). The loci identified in GWAS of the metabolome have presented with large
effect sizes and provide insight into the biological actions of the associated regions leading to an
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effect on the trait of interest53,54. For example, genetic markers may map near genes that encode
enzymes or transporters with a biological function relevant to the associated small molecule.
However, the majority of the genetic markers driving these GWAS signals do not directly map
to protein-encoding genes. One explanation is that the polymorphisms genotyped in GWAS are
not causal; rather they may be linked to and in linkage disequilibrium with a deleterious variant
that is directly driving the observed associations.
LOF allelic variation has great potential to influence the human metabolome but has not
yet been studied. First, this type of variation is predicted to have direct effects on gene action,
including metabolite levels and the proteins that regulate those levels. Thus, associations driven
by LOF variation may be very interpretable, especially if this variation disrupts the function of a
gene whose action may influence the metabolite of interest. In addition, this functional class of
variation is enriched at the rare end of the allele frequency spectrum compared to proteinaltering sequences. Thus, it seems likely that a significant portion of loci associated with
metabolome phenotypes may harbor rare LOF variation contributing to these associations.

Methods
Study Population
The Atherosclerosis Risk in Communities (ARIC) study is a prospective epidemiological
study designed to investigate the etiology and predictors of cardiovascular disease (CVD). A
detailed description of the ARIC study design and methods is published elsewhere40. Basic
cardiovascular risk factors were measured at each visit, and cardiovascular endpoints, such as
heart failure were ascertained annually using telephone interviews and hospital medical record
review. Detailed demographics are provided in Table 3.1.
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Table 3.1: Baseline Characteristics of African Americans in ARIC for whole exome sequencing
analyses (N=1,361). For continuous variables, mean values ± standard deviations are shown.
Circulation. Cardiovascular genetics: 8 January 2015 - Volume 8 - Issue 17 - p 351-355.
American Heart Association, Inc ©.

Characteristic
Age, years
Body mass index, kg/m2
Male, n (%)
Hypertension, n (%)
Diabetes, n (%)
Current smoker, n (%)
Prevalent coronary heart disease, n
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
HDL cholesterol, mg/dL
LDL cholesterol, mg/dL
Triglycerides, mg/dL
Total cholesterol, mg/dL

n (%) or Mean (SD)
52.5 ± 5.6
29.8 ± 6.2
464 (34.1)
705 (51.8)
190 (14.0)
377 (27.7)
49 (3.6)
126.9 ± 19.0
80.2 ± 11.4
56.1 ± 17.4
135.2 ± 38.0
106.2 ± 55.9
212.5 ± 40.0

.
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Metabolome Measurements
Metabolite profiling was measured using fasting serum samples collected from the
baseline visit (1987-1989) of ARIC African-Americans study participants. A total of 602
metabolites were detected and quantified by Metabolon Inc. (Durham, USA) using an
untargeted, gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass
spectrometry (LC-MS)-based metabolomic quantification protocols55,56. Metabolites were
excluded if: 1) more than 50% of the samples presented values below the platform detection
limit; or 2) the chemical structure was unknown. After filtering based on these criteria, a total
of 308 named metabolites were included in the present study; 83 amino acids, 16 carbohydrates,
9 cofactors and vitamins, 7 energies, 136 lipids, 12 nucleotides, 25 peptides and 20 xenobiotics
(Table 3.2).

Whole Exome Sequencing and Variant Validation
Whole exome sequence (WES) was performed using Illumina HiSeq 2000 (Illumina,
San Diego, CA, USA) and VCRome2.1 capture reagents (Roche NimbleGen, Madison, WI,
USA). Sequences were aligned to the hg19 reference genome using Burrows–Wheeler
Aligner42. Allele calling and variant call file (VCF) construction was performed using the
Atlas2 suite43 (Atlas-SNP and Atlas-Indel) to produce a VCF file. Single nucleotide variants
were excluded if they had a posterior probability less than 0.95, total depth of coverage less than
6x, allelic fraction < 0.1, 99% of reads in a single direction and homozygous reference alleles
with < 6x coverage. Low-quality indels were excluded if they had minimum total depth < 30,
allelic fraction < 0.2 for heterozygous variants and < 0.8 for homozygous variants and variant
reads < 10.
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Table 3.2: List of 308 metabolites included in this study. This table includes the category,
number of metabolites (n), and the names of specific metabolites included in these analyses.
Category
Amino acid

n
83

Carbohydrate 16

Cofactors
and vitamins

9

Energy

7

Lipid

Metabolites
2-aminobutyrate; 2-hydroxybutyrate (AHB); 2-hydroxyisobutyrate; 2methylbutyroylcarnitine; 3-(4-hydroxyphenyl)lactate; 3-hydroxy-2ethylpropionate; 3-hydroxyisobutyrate; 3-indoxyl sulfate; 3-methoxytyrosine;
3-methyl-2-oxovalerate; 3-methylhistidine; 3-phenylpropionate
(hydrocinnamate); 4-acetamidobutanoate; 4-guanidinobutanoate; 4-methyl-2oxopentanoate; 5-oxoproline; alanine; alpha-hydroxyisocaproate; alphahydroxyisovalerate; anthranilate; arginine; asparagine; aspartate; betahydroxyisovalerate; betaine; C-glycosyltryptophan; citrulline; creatine;
creatinine; cysteine; dimethylarginine (SDMA + ADMA); dimethylglycine;
glutamate; glutarate (pentanedioate); glutaroyl carnitine; glycine; histidine;
homocitrulline; homostachydrine; hydroxyisovaleroyl carnitine; indoleacetate;
indolelactate; indolepropionate; isobutyrylcarnitine; isoleucine;
isovalerylcarnitine; kynurenine; leucine; lysine; methionine; methionine
sulfoxide; N6-acetyllysine; N-acetylalanine; N-acetyl-beta-alanine; Nacetylglycine; N-acetylornithine; N-acetylphenylalanine; N-acetylserine; Nacetylthreonine; N-methyl proline; o-cresol sulfate; ornithine; p-cresol sulfate;
phenol sulfate; phenylacetate; phenylacetylglutamine; phenylalanine;
phenyllactate (PLA); pipecolate; proline; pyroglutamine; serine; serotonin
(5HT); stachydrine; threonine; tiglyl carnitine; trans-4-hydroxyproline;
tryptophan; tryptophan betaine; tyrosine; urea; urocanate; valine
1,5-anhydroglucitol (1,5-AG); 1,6-anhydroglucose; arabinose; erythronate;
erythrose; fructose; gluconate; glucose; glucuronate; glycerate; lactate;
mannitol; mannose; pyruvate; threitol; trehalose
alpha-tocopherol; arabonate; bilirubin (E,E); bilirubin (Z,Z); biliverdin;
gamma-tocopherol; pantothenate; pyridoxate; threonate

acetylphosphate; cis-aconitate; citrate; malate; phosphate; succinate;
succinylcarnitine
136 1,2 propanediol; 10-heptadecenoate (17:1n7); 10-nonadecenoate (19:1n9); 13HODE + 9-HODE; 1-arachidonoylglycerophosphocholine; 1arachidonoylglycerophosphoethanolamine; 1arachidonoylglycerophosphoinositol; 1docosahexaenoylglycerophosphocholine; 1docosapentaenoylglycerophosphocholine; 1eicosadienoylglycerophosphocholine; 1-eicosatrienoylglycerophosphocholine;
1-heptadecanoylglycerophosphocholine; 1-linoleoylglycerophosphocholine; 1linoleoylglycerophosphoethanolamine; 1-myristoylglycerophosphocholine; 1O-hexadecylglycerophosphocholine; 1-oleoylglycerol (1-monoolein); 1oleoylglycerophosphocholine; 1-oleoylglycerophosphoethanolamine; 1palmitoleoylglycerophosphocholine; 1-palmitoylglycerol (1-monopalmitin); 1palmitoylglycerophosphocholine; 1-palmitoylglycerophosphoethanolamine; 1palmitoylglycerophosphoinositol; 1-pentadecanoylglycerophosphocholine; 1stearoylglycerol (1-monostearin); 1-stearoylglycerophosphocholine; 1stearoylglycerophosphoethanolamine; 1-stearoylglycerophosphoinositol; 21hydroxypregnenolone disulfate; 2-arachidonoylglycerophosphocholine; 2arachidonoylglycerophosphoethanolamine; 2-hydroxyglutarate; 2hydroxyoctanoate; 2-hydroxypalmitate; 2-hydroxystearate; 2linoleoylglycerophosphocholine; 2-linoleoylglycerophosphoethanolamine; 2oleoylglycerophosphocholine; 2-oleoylglycerophosphoethanolamine; 2palmitoylglycerophosphocholine; 2-palmitoylglycerophosphoethanolamine; 2-
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stearoylglycerophosphocholine; 3-carboxy-4-methyl-5-propyl-2furanpropanoate (CMPF); 3-dehydrocarnitine; 3-hydroxybutyrate (BHBA); 3hydroxydecanoate; 4-androsten-3beta,17beta-diol disulfate 1; 4-androsten3beta,17beta-diol disulfate 2; 5alpha-androstan-3beta,17beta-diol disulfate;
5alpha-pregnan-3beta,20alpha-diol disulfate; 5-dodecenoate (12:1n7); 5-HETE;
7-alpha-hydroxy-3-oxo-4-cholestenoate (7-Hoca); 7-beta-hydroxycholesterol;
acetylcarnitine; adipate; adrenate (22:4n6); andro steroid monosulfate 2;
androsterone sulfate; arachidonate (20:4n6); azelate (nonanedioate); caprate
(10:0); caproate (6:0); caprylate (8:0); carnitine; cholate; cholesterol; choline;
cis-vaccenate (18:1n7); cortisol; cortisone; decanoylcarnitine;
dehydroisoandrosterone sulfate (DHEA-S); deoxycarnitine; deoxycholate;
dihomo-linoleate (20:2n6); dihomo-linolenate (20:3n3 or n6);
docosahexaenoate (DHA; 22:6n3); docosapentaenoate (n3 DPA; 22:5n3);
docosapentaenoate (n6 DPA; 22:5n6); dodecanedioate; eicosapentaenoate
(EPA; 20:5n3); eicosenoate (20:1n9 or 11); epiandrosterone sulfate; glycerol;
glycerol 3-phosphate (G3P); glycerophosphorylcholine (GPC);
glycochenodeoxycholate; glycocholate; glycocholenate sulfate;
glycodeoxycholate; glycolithocholate sulfate; heptanoate (7:0);
hexadecanedioate; hexanoylcarnitine; hyodeoxycholate; inositol 1-phosphate
(I1P); isovalerate; laurate (12:0); laurylcarnitine; linoleate (18:2n6);
linolenate[alpha or gamma; (18:3n3 or 6)]; margarate (17:0); methyl palmitate;
myo-inositol; myristate (14:0); myristoleate (14:1n5); nonadecanoate (19:0);
octadecanedioate; octanoylcarnitine; oleate (18:1n9); oleoylcarnitine; palmitate
(16:0); palmitoleate (16:1n7); palmitoyl sphingomyelin; palmitoylcarnitine;
pelargonate (9:0); pregn steroid monosulfate; pregnen-diol disulfate;
propionylcarnitine; scyllo-inositol; sebacate (decanedioate); stearate (18:0);
stearidonate (18:4n3); stearoyl sphingomyelin; stearoylcarnitine; suberate
(octanedioate); taurochenodeoxycholate; taurocholate; taurocholenate sulfate;
taurolithocholate 3-sulfate; tetradecanedioate; undecanedioate; undecanoate
(11:0); valerate
Nucleotide 12
5-methyluridine (ribothymidine); 7-methylguanine; adenosine; allantoin;
guanosine; hypoxanthine; inosine; N1-methyladenosine; pseudouridine; urate;
uridine; xanthine
Peptide
25
[H]HWESASLLR[OH]; alanylleucine; alpha-glutamylglutamate;
aspartylphenylalanine; bradykinin, des-arg(9); DSGEGDFXAEGGGVR;
gamma-glutamylalanine; gamma-glutamylglutamate; gammaglutamylisoleucine; gamma-glutamylleucine; gamma-glutamylphenylalanine;
gamma-glutamylthreonine; gamma-glutamyltyrosine; gamma-glutamylvaline;
glycylleucine; glycylphenylalanine; glycyltyrosine; glycylvaline; HWESASXX;
HXGXA; leucylleucine; leucylphenylalanine; pro-hydroxy-pro;
pyroglutamylglycine; threonylphenylalanine
Xenobiotics 20
1,7-dimethylurate; 1-methylurate; 2-hydroxyhippurate (salicylurate); 3ethylphenylsulfate; 4-ethylphenylsulfate; 4-hydroxyhippurate; 4-vinylphenol
sulfate; 5-acetylamino-6-amino-3-methyluracil; benzoate; caffeine; catechol
sulfate; erythritol; glycerol 2-phosphate; hippurate; paraxanthine; piperine;
salicylate; theobromine; theophylline; thymol sulfate
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Following statistical analysis, all significantly associated variants were validated using
an orthogonal laboratory technology (i.e. Array-based genotyping44, Sequenom genotyping, or
Sanger sequencing). All reported genotypes driving associations were successfully validated.

Statistical Analyses
LOF variants included in this study were defined as premature stop codons occurring in
the non-terminal gene exon, essential splice site disrupting (+ 2bp), and indels predicted to
disrupt downstream reading frame. T5 tests32 were performed to evaluate the joint effects of
rare alleles (MAF<5%) in a gene, and were conducted on each metabolite after adjusting for
age, gender, estimate glomerular filtration rate calibrated (eGFR)57 and population structure.
Statistical significance was defined as a p-value < 1.3 × 10-7 for T5 tests (Bonferroni correction
of 395,780 tests: 1,285 genes × 308 metabolites). Metabolite levels were natural logtransformed prior to the analysis. All the analyses were performed using R (www.r-project.org).

Results
Metabolite associations
WES of the 1,361 African-American ARIC participants also measured for these
metabolites revealed 12,522 polymorphic LOF variants (5,060 stopgains, 2,599 splice and 4,863
frameshift indels) representing 7,038 genes. Each sample contained an average of 111.7
heterozygous and 14.5 homozygous LOF variants.
The effect of LOF variation on 308 metabolites was analyzed by gene-based aggregation
of these variant sites. Eight genes harboring 17 LoF variants (7 stopgains, 3 splice and 7
frameshift indels) were identified to be significantly associated with eight metabolites levels (p
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< 1.3 × 10-7, Table 3.3), and these variants were related to 19-50% change of the geometric
mean for metabolite levels depending on the particular metabolite. As expected26, we observed
that LOF variants in PCSK9 had lower cholesterol levels compared to the non-carriers (p =
5.4×10-9). However, we also highlight several novel associations with compelling underlying
biology.
We observed 3 LOF variants in the gene Histidine Ammonia Lyase (HAL) that were
strongly associated with decreased levels of Histidine (published, 2015)58. Histidine is an
antioxidant and anti-inflammatory factor (Figure 3.1a). In addition to these features, HAL
plays an essential role in the catabolism of Histidine (Figure 3.2b). The 24 carriers of LOF
variation in this gene collectively presented a 29.7% increase in histidine’s geometric mean and
explained 4.8% of its variance (Figure 3.1c), and the direction of this effect (increase) is
consistent with the expectation given the role of HAL in Histidine biology. The association
between R322X was replicated in an independent samples of 718 ARIC study participants with
both exome chip data and serum histidine levels (p=1.2x10-4)58.
We also observed a LOF splice variant in SLCO1B1 which was associated with high
levels of hexadecanedioate (p = 2.2×10-9), a C16 dicarboxylic acid (manuscript submitted).
SLCO1B1 is an organic ion transporter expressed at high levels in the liver59, and follow-up
studies showed this variant has pleiotropic effects on tetradecanedioate, a C14 dicarboxylic acid
(p = 9.0×10-5).
Considering that LOF may act recessively, we also observed samples with homozygous
stop mutations in two genes (LRRC69, SLCO1B1) who also presented extreme values for
metabolites. The presentation of hexadecanedioate within SLCO1B1 heterozygotes is described
above, but the single homozygous sample presented levels of this metabolite in the tail of this
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Table 3.3. Eight significant gene-metabolite associations identified among African Americans
in ARIC. SE = standard error; cMAC = cumulative minor allele count.
Metabolite

Pathway

Gene

P

Beta (SE)

cMAC

Histidine

Amino acid

HAL

2.3×10-13

0.23 (0.03)

26

Methionine sulfoxide

Amino acid

C6orf25

1.3×10-8

-0.45 (0.08)

9

Mannose

Carbohydrate

TEX15

7.9×10-9

-0.70 (0.12)

10

Cholesterol

Lipid

PCSK9

5.4×10-9

-0.21 (0.04)

30

Deoxycarnitine

Lipid

LRRC69

8.5×10-16

-0.42 (0.05)

17

Hexadecanedioate

Lipid

SLCO1B1

2.2×10-9

0.38 (0.06)

67

5-HETE

Lipid

FAM198B

4.5×10-9

-0.38 (0.07)

14

Urate

Nucleotide

LRRC46

1.1×10-7

-0.44 (0.08)

10

.
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Figure 3.1: HAL LOF alleles and their association with histidine levels. (A) Three LOF
variants in HAL among African Americans in ARIC; (B) Flow chart of HAL gene function; (C)
Histidine levels in HAL LOF carriers and noncarriers, the error bard indicate standard deviation.
Image via: Circulation. Cardiovascular genetics: 8 January 2015 - Volume 8 - Issue 17 - p 351355. American Heart Association, Inc ©.

45

distribution (Figure 3.2b). Similarly, we observe extremely low levels of deoxycarnitine in a
single sample with homozygous LOF variation in LRRC69 (Figure 3.2a).

Discussion
Using high-throughput metabolomic and genomic sequence technologies, we carried out
extensive analysis to evaluate the effect of predicted LOF mutations on the human serum
metabolome. This study identified nine genes that were associated with ten metabolite levels
among African-Americans, and seven out of the nine genes represent novel findings (Table
3.3). Our results provide new insights into the genetic architecture of the human metabolome
among African-Americans, including the possible identification of LOF variation as a
biomarker for a protective effect against coronary heart disease58.
Inborn errors formed the earliest understanding of genetic architecture on human
metabolism60. Over a hundred genes with multiple variants were reported to be associated with
multiple metabolites by GWASs of the metabolome53,61, but only in a few cases has the
underlying functional variant(s) been identified that are responsible for the observed association.
Thus far, hundreds of causal genes for severe inherited disorders of metabolism have been
discovered, and the majority of the causal variants identified have been shown to be rare.
Sequencing large numbers of samples and annotating clear functional categories of the detected
variations provides one path leading toward identifying novel genes and variants contributing to
complex phenotypes. Here, we report here that LOF mutations observed in the general
population are related to human metabolome, and this approach provides a strategy for
identifying novel disease genes.
Histidine is an essential amino acid in humans and other mammals, and a precursor for
histamine and carnosine biosynthesis. The enzyme encoded by HAL catalyzes the first reaction
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Figure 3.2. Distribution of metabolite levels among LoF mutation carriers in ARIC. (a) Low
serum deoxycarnitine level in a single LRRC69 LoF homozygote; (b) high serum
hexadecanedioate levels in SLCO1B1 LoF heterozygotes
zygotes and a single homozygote.
homozygote
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in Histidine catabolism, and missense mutations in this gene cause autosomal recessive
histidinemia (MIM:609457). Histidine levels in the blood exceeding 6 mg/dL are one marker
for the diagnosis of this disorder. In this study, 24 study participants with LOF variation in HAL
present elevated serum histidine (mean 1.5 mg/dL; Figure 3.1; Figure 3.3), suggesting a milder
subclinical form may be present in these carriers. Histidine has anti-inflammatory properties62
and low levels are associated with inflammatory diseases such as chronic kidney disease63 and
rheumatoid arthritis64. Inflammatory cytokines are also related to the early stages of
atherosclerosis and coronary heart disease (CHD)65. Follow-up analyses within ARIC and other
cohorts revealed an association between high levels of histidine and a reduced risk for CHD58.
These results suggest that HAL and other members of the nuclear factor-κB pathway66 may
represent therapeutic targets for CHD and other inflammatory disorders.
Common non-functional variants tagging SLCO1B1 have been reported in GWAS to be
associated with fatty acids levels, including tetradecanedioate and hexadecanedioate53.
SLCO1B1 encodes a protein that mediates the cellular uptake of numerous endogenous
compounds and is involved in clearing many drug compounds, including the statin drug class
which lowers cholesterol67. In this study, we observed associations between LOF variation in
SLCO1B1 with tetradecanedioate and hexadecanedioate. Little is known about these two
medium chain fatty acids, except a recent study showed that their levels are increased in the
lung tissue of patients with pulmonary arterial hypertension (PAH)68. Follow up analyses reveal
that LOF alleles in SLCO1B1 are associated with high risk of heart failure in an extended
sample of ARIC participants (data not shown). The findings indicate a possible causal effect of
SLCO1B1 on HF via altered fatty acids metabolism and uptake.
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Figure 3.3: Quantile-quantile
quantile plots of T5 test on histidine levels in ARIC African Americans.
Circulation. Image adapted from: Cardiovascular genetics: 8 January 2015 - Volume 8 - Issue
17 - p 351-355. American Heart Association, Inc ©.

49

The mechanisms potentially underlying other associations we detected are less clear. As
the collection of data (genetic and phenotypic) becomes increasingly larger, granular, and higher
quality, interpretation of findings rather than data collection become rate limiting. Crossreferencing analytical results with large public databases cataloguing metabolite function, such
as the Human Metabolome Database (HMDB, http://www.hmdb.ca/) is a one approach to
interpret associations with the greatest potential to impact healthcare. This data-driven approach
does not preclude the collaboration between genetic analysts, clinicians, and phenotype
specialists; rather it serves as additional tool for facilitating discovery. In addition, model
organisms remain an essential tool for the study of specific mutational activity in vivo, although
they are not high-throughput and rely on the a priori detection of strong analytical candidates.
In summary, we report here the first whole exome LOF study of the untargeted
metabolome in African-Americans. Our findings illuminate the value of utilizing deep
phenotype collection methods (“-omic”) studies in cohort studies to provide new insights and
generate new hypotheses into gene function and disease etiology. We identify LOF variation in
eight genes which may make promising drug targets, especially HAL which regulates histidine
and is linked to lowered risk of coronary heart diseae58. While the analysis of large “-omic”
data sets may seems like an insurmountable challenge for researchers, these findings reveal that
functional and biological paradigms (such as LOF variation) can be used to inform association
studies and make significant and clinically interpretable findings.
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Chapter 4: Rare Congenital Cardiovascular Malformation
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Introduction
Severe congenital cardiovascular malformations (CVMs) occur in 5-8/1000 live births
and have a high mortality rate compared to other birth defects69,70. Left Ventricular Outflow
Tract Obstructions (LVOTO) comprise 15-20% of severe CVMs71,72 , and include Hypoplastic
Left Heart Syndrome (HLHS), Aortic Valve Stenosis (AS), Coarctation of the Aorta (CoA),
Interrupted Aortic Arch Type A (IAAA), Mitral Stenosis and Shone Complex (Figure 4.1).
This diverse family of cardiac conditions share underlying mechanisms driven by altered or
obstructed blood through the left side of the heart during development73.
Genetic contributions to the development of LVOTO are complex and include single
nucleotide substitutions, chromosome abnormalities74, genomic disorders75 and oligogenic
inheritance76. Over 30 genes have been previously implicated in human syndromes including
LVOTO-type malformations. These loci include HLHS ( ZIC3, TBX5, CREBBP, ACVR2B,
LEFTY2, DTNA, DHCR7, EVC1-2, FOXF1-FOXC2-FOXL1, and PEX genes), AS (NOTCH1,
FOXC1, FGD1), CoA (JAG1, NOTCH2, NF1, PTPN11, KRAS, SOS1, RAF1, NRAS, BRAF,
SHOC2, CBL, ZIC3, CREBBP, MLL2, FGD1, DHCR7, NSDHL, KCNJ2, MKS1) (Table 4.1).
Familial clustering of cases77 and an increased risk of LVOTO in first-degree relatives78 are
consistent with single gene or oligogenic inheritance. However, the fact that many cases are
sporadic also suggests a role for de novo mutations and other rare chance events. Zaidi et al79
report the occurrence of de novo mutations in a cohort of congenital heart defect cases, albeit
without respect to a specific CVM type.
To gain a deeper understanding of the spectrum of genetic variation associated with
LVOTO, we performed whole-exome sequencing of a cohort of 342 LVOTO patients without
extra-cardiac features. Variant frequencies were compared to multiple population data
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Figure 4.1. Representation of Hypoplastic Left Heart Syndrome features. This figure depicts
the spectrum of cardiovascular malformation associated with HLHS, a feature of LVOTO.
Other LVOTO features include aortic valves stenosis (AS), coarctation of the aorta (CoA),
interrupted aortic arch type A (IAAA), mitral stenosis and Shone Complex (Supravalvular
mitral membrane, parachute mitral valve, suba
subaortic stenosis, & CoA).
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Table 4.1: List of genes causing human phenotypes overlapping LVOTO. HLHS = hypoplastic
left heart syndrome ; AS = aortic stenosis; CoA = Coarctation of the aorta. Shone complex
includes supravalvular mitral membrane, parachute mitral value, subaortic stenosis and CoA.
Gene

HLHS

AS

CoA

IAA

Shone complex

ACVR2B

✓

.

.

.

.

BRAF

.

.

.

.

CBL

.

.

✓
✓

.

.

CHD7

.

.

.

✓

.

CREBBP

.

.

.

.

✓
✓

.

.

.

.

.

.

EVC,EVC2

✓
✓
✓
✓

.

.

.

.

FGD1

.

✓

.

.

FOXC1

.

✓
✓

.

.

.

FOXF1-FOXC2-FOXL1 deletion

✓

.

.

.

.

JAG1

.

.

.

.

KCNJ2

.

.

.

.

KRAS

.

.

✓
✓
✓

.

.

LEFTY2

✓

.

.

.

MKS1

.

.

.

.

MLL2

.

.

.

.

NF1

.

.

.

.

NOTCH2

.

.

.

.

NRAS

.

.

NSDHL

.

.

PEX genes

✓

.

PTPN11

.

.

RAF1

.

.

SHOC2

.

.

SOS1

.

TBX1
TBX5

DHCR7
DTNA

ZIC3

✓
✓
✓
✓
✓
✓

.
.

✓

.

.

.

.

.

.

.

.

.

✓
✓
✓
✓

.

.

.

.

.

✓

.

✓
✓

.

.

.

.

.

✓

.

.
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resources (1000 genomes, ESP, ExAC) and 5,492 individuals from the ARIC study without
severe cardiac malformation sequenced on the same platform. We first constructed a list of a
priori candidate cardiac malformation genes which includes those implicated in similar human
disorders, overlapping phenotypes in model organism knockouts, and expression in the
developing heart tissue. The intersection of this candidate gene filter with rare loss-of-function
(LOF) variation within cases identified implicating mutations in 9% of LVOTO cases, including
nine de novo point mutations and three genes with recessive or hemizygous inheritance.
These results highlight the complex genetics contributing to LVOTO, and the utility of
exome sequencing in a large informative sample set to identify novel genes or gene mutations
for a rare disease. The general analysis framework we present may also apply to similar
sequence-based analyses of rare disease cohorts of unrelated individuals (Figure 4.2).
Methods
Sample Selection
This study included 342 unrelated LVOTO cases without known extracardiac
malformations or unexplained developmental delay ascertained from the Texas Medical Center
in Houston, TX (Table 4.2). Parents and affected family members (if any) of LVOTO cases
were also recruited as study participants. Our analyses also included 5,492 European American
(EA) individuals from the population-based Atherosclerosis Risk in Communities (ARIC)
study40 as a comparison group for variant filtering and statistical analyses. ARIC samples with
any of the following criteria were excluded from these analyses: prevalent heart failure, major
Q-wave, or LVH by the Cornell definition. In addition, as a validation/replication set we
examined 4,750 independent cases referred for clinical exome sequencing at the Baylor Miraca
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Figure 4.2. Discovery strategy for LVOTO cohort. Imposing a candidate list, constructed
independently, of disease gene candidates over exome
exome-wide
wide analyses facilitates genes discovery
in rare disease cohorts.
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Table 4.2. Overview of LVOTO cases. This table summarizes basic demographical and clinical
information of 342 LVOTO probands.

Ethnicity
African
Caucasian
Hispanic
Total

Sex
Female Male
0
1
83
163
25
70
108
233

Total
1
246
95
342
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Genetics Laboratory (http://www.bmgl.com) for rare LOF variants in a subset of genes given
priority after analysis of the initial research discovery set of 342 cases.

Whole-exome sequencing
Whole exome sequencing (WES) was performed on cases and comparison samples with
the Illumina HiSeq platform using the Mercury pipeline41. ARIC samples were captured using
VCRome 2.1 (42Mb) reagents with an average coverage of 88x, LVOTO cases were captured
using HGSC core (52Mb), and all analyses were restricted to exonic regions shared between
these two reagents. Read mapping to Genome Reference Consortium Human Build 37
(GRCh37) was performed with Burrows-Wheeler alignment42, and allele calling was performed
with the Atlas2 suite (Atlas-SNP, Atlas-Indel)43. The Variant Call File (VCF) contained flags
for low-quality variants which were excluded from all analyses, including SNPs with poster
probability lower than 0.95, total depth of coverage less than 10x, fewer than 3 variant reads,
allelic fraction less than 10%, 99% reads in a single directions, and homozygous reference
alleles with < 6x coverage. In addition, we removed low-quality indels with a total depth less
than 30x and allelic fraction below 30%. Individuals presenting extremely high or low numbers
of heterozygous variant sites (6 standard deviations) were flagged and excluded from the burden
analyses.

A priori gene prioritization
To facilitate novel gene and variant discovery, we compiled a priori evidence from
public resources to identify potential novel LVOTO genes. We compiled a list of 1,712 human
genes with a putative role in the development of cardiovascular malformation from a variety of
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public resources. Genes related to overlapping human disorders including CVM were
ascertained from NCBI and literature searches. Relevancy to biological pathways and
interactions (Hedgehog, NOTCH, TGFB, PITX2) was determined using the Kyoto Encyclopedia
of Genes and Genomes (KEGG) database8081. Two model organism databases (ZFIN82, MGI83)
were also used to ascertain additional genes with a potential role in cardiovascular development.
ZFIN was queried for genes expressed in the zebrafish heart, and MGI was queried for genes
causing abnormal cardiac morphology in mouse models (MP:0000266). Additional quantitative
measures used to prioritize genes included (a) measures of observed LOF prevalence (OP
ratio25), (b) tolerance to functional variation (RVIS48) and (c) the probability of de novo
mutation84. Gene expression in the heart was gathered from the literature79 and Tissue-specific
Gene Expression and Regulation (TiGER) database (http://bioinfo.wilmer.jhu.edu/tiger/).

Variant annotation
Variants were annotated to Refseq gene definitions using ANNOVAR85. Conservative
loss-of-function (LOF) annotation was performed by selecting premature stopgains in the nonterminal exon, variants disrupting essential splice sites used by all gene isoforms, and frameshift
indels similarly mapping to all isoforms. Damaging nonsynonymous (DNS) variation was
defined as protein-altering substitutions predicted to be damaging by a consensus of at least 3
out of 6 prediction scores downloaded via dbNSFP29 (SIFT, Polyphen2 HDIV, LRT, Mutation
Taster, Mutation Assessor, FATHMM). A PHRED-like scaled C-score (CADD86) was also
used to assess pathogenicity of variants (LOF and DNS), but was not used to exclude candidate
sites.
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Analytical methods
Initially, we focused on the most damaging class of variation (extremely rare LOF) and
considered multiple modes of Mendelian inheritance. We first identified all LOF sites exclusive
to cases which included heterozygous (dominant), homozygous (recessive), hemizygous (Xlinked males) or multiple compound-heterozygous genotypes in a given gene (recessive).
Fisher’s exact test was used to compare allele frequencies in LVOTO cases to ARIC study
participants. Within the set of genes presenting case-exclusive LOF variation, we next
performed “functional expansion” to include similarly-segregating DNS sites, which were
analyzed by the same methods (Figure 4.3).
Firth logistic regression87 was used to assess more complex genetic models by grouping
rare DNS variation (observed MAF <1%). Using case-control status as an outcome, the total
number of heterozygous sites per individual was included in the model as a covariate to address
platform differences between sequencing batches. We defined a p-value of 2.86 x10-6 as
statistically significant for burden analyses by performing a Bonferroni correction for the
number of genes harboring DNS (n=17,487).
After these exome-wide analyses, we further enriched for genes likely to contribute to
LVOTO in two ways. First, for each gene the sum of all observed LOF alleles in ARIC was
calculated (gene-wise observed LOF) and compared to all potential simulated LOF sites to
calculate the ratio of observed to potential LOF alleles (OP ratio25). Only genes with a very low
OP ratio (zero, or lowest 30th percentile) were considered strong candidates for disease. In
addition, we filtered for the set of cardiac genes compiled a priori (Figure 4.1) to identify those
with supporting evidence for a role in LVOTO.
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Figure 4.3: Detailed analytical framework to assess in rare disease cohorts. This figure depicts
a 2-stage
stage analysis strategy used to assess whole
whole-exome
exome sequence (WES), with emphasis on LOF
variation and follow-up
up using DNS variation. In the variant selection stage (yellow), high
quality sites are identified, annotated for functional effect and population frequency. Rare LOF
variation is analyzed by three inheritance models (orange) to identify case
case-exclusive
exclusive LOF sites.
Next, gene prioritization (green) compares an a priori list of gene candidates to identify the best
gene candidate with both genetic and biological support. Variants are then validated (blue) in
probands and parents when available to detect de novo inheritance. Finally, functional
expansion into DNS
NS alleles is then performed within the set of genes identified by LOF.
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All variants identified to be potentially related to the development of LVOTO were
validated via Sanger sequencing. Only those variants sites that did validate are reported here.
Results
Exome sequence variation
WES of LVOTO cases initially revealed 243,609 variants within the VCRome capture
regions (239,726 single nucleotide substitutions, and 3,883 small indels ranging from -51 to +26
nucleotides in length). On average, each case presented with 14,669 heterozygous and 8,321
homozygous non-reference genotypes (Table 4.3). Thirty samples presented extremely high or
low heterozygosity (4 cases, 26 controls; beyond 6 standard deviations from sample mean) and
were excluded from burden analyses.
Annotation of exonic sites to multiple population data resources (ESP, 1000 Genomes,
ExAC) revealed that 132,182 of the total LVOTO variants sites (129,329 SNV, 2,853 indel)
were either novel or extremely rare (MAF 0.5%) in the comparison groups. Functional
annotation revealed 4,161 rare predicted LOF variants (1,469 premature stop, 602 splice, and
2,090 frameshift) in 1,660 genes, and 34,100 DNS variants in 11,822 genes. The mean number
of these rare variants per LVOTO patient was 54.4 LOF and 118.8 DNS (range LOF = 35-74;
range DNS = 88-158, Figure 4.4).

LOF variation in LVOTO cases reveals known and novel cardiac genes
Twenty nine genes from our a priori cardiac gene candidate list harbored case-exclusive
LOF alleles (Table 4.4). Sanger sequencing of these alleles in parents revealed nine to have
arisen de novo, all in different genes (ACVR1, JARID2, KMT2D, NF1, NR2F2, PLRG1,
SMURF1, TBX20, and ZEB2). Mutations in NF1 (MIM 162200), NR2F2 (MIM 615779), TBX20
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Table 4.3: Summary of non-reference genotypes in exome sequence samples. This table
describes the average value per individual, with standard deviation in parenthesis.

Het
Homo
Ti
Tv
TiTv

ARIC
14,493.97 (587.73)
8,204.09 (301.99)
22,895.69 (744.71)
7,582.58 (264.27)
3.02 (0.03)

LVOTO
14,669.61 (986.81)
8,321.78 (534.60)
23,084.29 (1,442.65)
7,669.32 (485.89)
3.01 (0.031)
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Figure 4.4: Distribution of rare sites within LVOTO cases. These histograms depict the
number of rare (a) DNS and (b) LOF sites per sample.
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Table 4.4: Discovery genes presenting case-exclusive LOF sites and evidence for a role in
LVOTO. This table highlights 29 genes with rare LOF sites in LVOTO cases and supporting
evidence for a role in cardiac malformation. The number of samples in the Baylor Miraca lab
presenting CVM and LOF alleles, distinct from LVOTO cases, is provided. One LVOTO case
presenting mutation in multiple candidates is denoted (ǂ). Unknown inheritance indicates only
parent was available for validation that did not carry the mutation. Gene support symbols are
defined as follows: CVM = known role in human cardiovascular malformation, MGI =
overlapping phenotype in mouse, HE = human heart expressed ; PITX2 = related to PITX2
transcription; ZFIN = overlapping phenotype in zebrafish; TGFB = TGFB pathway.
LVOTO
mode
de novo

Inherited

X-linked
Recessive
Unknown

Gene

Chrom.

LVOTO
cases

BCM Miraca
CVM

Gene support

ACVR1
JARID2
KMT2D
NF1
NR2F2
PLRG1
SMURF1
TBX20
ZEB2
ARHGEF11
CCDC91
CDH2
E2F6
FGF19
GJC1
GLRX3
LATS2
LTBP1
PCDHGA2
PCSK6
RAC1
OFD1
DNAH5
MNDA
JMJD6
BMP1
KMT2D
ROCK1

2
6
12
17
15
4
7
7
2
1
12
18
2
11
17
10
13
2
5
15
7
X
5
1
17
8
12
18

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1ǂ
1
1
1ǂ

0
1
7
1
0
0
1
0
6
2
1
0
0
0
0
0
2
1
0
3
1
1
0
0
0
0
7
0

MGI,HE,TGFB
MGI,PITX2
CVM
CVM,MGI,HE
MGI
MGI
TGFB
CVM,MGI,HE
ZFIN, CVM
ZFIN
PITX2
MGI,HE,PITX2
PITX2
MGI
MGI,ZFIN
MGI,HE
MGI
MGI,TGFB
HE
MGI
MGI,HE
CVM,MGI,ZFIN
CVM,MGI,HE,PCD
CHD candidate
MGI
MGI
CVM
MGI,TGFB,PITX2

LOF
OP
(%ile)
0.201
0
0
0.166
0
0
0
0
0
0.156
0
0.077
0
0
0
0
0.119
0
0
0
0
0
0.299
0.265
0
0
0
0
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(MIM 611363) and ZEB2 (MIM 235730) are known to cause human genetic disorders, and
cardiac malformations in these syndromes occur in 3% to 50% of patients. SMURF1 is
involved in the TGFB pathway, JARID2 is regulated by the PITX2 transcription factor that has
been associated with cardiac malformation, and mutant alleles in PLRG1 cause malformation of
the left ventricle in mouse model systems88. We expanded our evaluation of these genes to
include DNS variants that were absent in controls or in public data resources. In this analysis,
we identified three additional de novo variants (KMT2D, TBX20, ZEB2), providing further
evidence for their role as primary LVOTO genes (Table 4.5).
Transmitted LOF variants were present in the heterozygous state, with the exception of
DNAH5, MNDA, and OFD1. One LVOTO case presented a homozygous LOF variant in
DNAH5, which is reported to cause ciliary dyskinesia, primary, 3, with or without situs inversus
(MIM 608644), a known autosomal recessive condition. Two frameshift mutations were
observed within in another case located in MNDA (Sanger validated, trans-inherited), a gene
which has been previously suggested as an LVO candidate79. Mutations in OFD1 (X-linked)
cause Joubert syndrome, which can include congenital heart malformation within its phenotypic
spectrum89. These observations support recessive and sex-linked forms of LVOTO, highlighting
the complex genetics underlying this disease.

Aggregation of DNS variation
Expanding the scope of inheritance models, we next grouped rare variation by genes and
pathways to detect enrichment of deleterious alleles in the sample of LVOTO cases.
Aggregating DNS variation by gene revealed significant enrichment of rare alleles in 19 genes
(MAF<1%, p < 2.86 x10-6), including one gene (DDX11) present in the list of a priori
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Table 4.5 . List of all Sanger-validated sites in LVOTO cases. Variant fields (“:” delimited)
are chromosome, hg19 position, reference allele, alternative allele; CADD v1.2 PHRED-like
scales scores obtained online (http://cadd.gs.washington.edu/score); RVIS downloaded from
Petrovski et al48; OP ARIC ratio calculated from ARIC EA samples; OP ExAC from v0.3, total
AC field. “NA” in OP ratio field indicates zero LOF alleles observed in this gene by our custom
stringent annotation methods.
Inheritance

Gene

Variant

Variant
Type

n

CADD

RVIS
(%ile)

OP
ARIC
(%ile)

OP
ExAC
(%ile)

inherited

NOTCH2

1:120458122:A:T

DNS

1

19.38

2.15

0.011

0.978

inherited

ARHGEF1
1:156905835:A:AG frameshift 1
1

35

2.5

0.156

0.131

inherited

MNDA

1:158812053:CA:C frameshift 1

19.18

67.3

0.265

0.869

inherited

MNDA

1:158812100:GAAA
frameshift 1
A:G

23.3

67.3

0.265

0.869

unknown

ROR1

1:64644454:C:G

stopgain

1

37

3.05

NA

0.107

inherited

GLRX3

10:131959078:C:T

stopgain

1

19.57

48.35

NA

0.176

inherited

LGR4

11:27390487:TTAG
frameshift 1
GATGCCAG:T

37

34.88

0.128

0.51

inherited

FGF19

11:69514190:TGA:T frameshift 1

35

NA

NA

0.12

inherited

CCDC91

12:28459810:C:T

stopgain

1

38

91.26

NA

0.337

de novo

KMT2D

12:49416115:G:A

stopgain

1

22.7

NA

NA

NA

de novo

KMT2D

12:49420607:G:A

DNS

1

24.7

NA

NA

NA

unknown

KMT2D

12:49445202:C:CG frameshift 1

23.1

NA

NA

NA

inherited

LATS2

13:21557671:TTGT
frameshift 1
C:T

37

74.71

0.119

0.155

inherited

SGCG

13:23808789:C:T

DNS

1

34

43.77

NA

0.493

inherited

PCSK6

15:101866685:C:T

splicing

1

19.11

NA

NA

0.161

de novo

NR2F2

15:96875777:G:T

splicing

1

22.2

26.23

NA

NA

de novo

NF1

17:29562641:C:T

stopgain

1

41

0.47

0.166

0.916

inherited

NF1

17:29670054:C:T

DNS

1

22.3

0.47

0.166

0.916

inherited

NF1

17:29677234:G:A

DNS

1

22.3

0.47

0.166

0.916

inherited

GJC1

35

44.89

NA

NA

17:42882475:AC:A frameshift 1
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inherited

JMJD6

17:74714943:C:A

frameshift 1

unknown

ROCK1

inherited

CDH2

18:25564963:C:T

splicing

de novo

SMAD7

18:46474796:G:T

unknown

GATAD2A

19:19576173:C:T

inherited

E2F6

de novo

ZEB2

2:145153979:C:A

stopgain

de novo

ZEB2

2:145187539:T:C

de novo

ACVR1

inherited

27.2

18.44

NA

0.269

35

18.9

NA

0.222

1

33

7.52

0.077

0.257

DNS

1

18.05

NA

NA

0.907

stopgain

1

36

9.27

NA

0.109

23.2

56.64

NA

0.234

1

48

10.03

NA

0.011

DNS

1

22.3

10.03

NA

0.011

2:158637081:G:T

stopgain

1

35

21.41

0.201

0.205

LTBP1

2:33526713:T:G

splicing

1

25.5

24.47

NA

0.12

de novo

PLRG1

4:155460345:G:A

stopgain

1

22.3

33.2

NA

0.856

inherited

DNAH5

5:13868103:TA:T

frameshift 1

0.781

40.16

0.299

0.969

inherited

PCDHGA2

35

70.78

NA

NA

inherited

JARID2

6:15374390:C:T

DNS

1

21.6

2.42

NA

0.448

inherited

JARID2

6:15487603:G:C

DNS

1

22.5

2.42

NA

0.448

inherited

JARID2

6:15496604:A:G

DNS

1

24.5

2.42

NA

0.448

unknown

JARID2

6:15496768:C:T

DNS

1

35

2.42

NA

0.448

de novo

JARID2

6:15508596:TG:T

frameshift 1

38

2.42

NA

0.448

de novo

TBX20

7:35244085:G:A

stopgain

1

39

12.77

NA

0.177

inherited

TBX20

7:35244154:G:A

DNS

1

34

12.77

NA

0.177

de novo

TBX20

7:35289584:A:G

DNS

1

19.24

12.77

NA

0.177

inherited

RAC1

7:6438350:G:A

splicing

1

27.8

41.25

NA

NA

de novo

SMURF1

36

4.39

NA

0.292

inherited

SMURF1

7:98649062:G:C

DNS

1

22

4.39

NA

0.292

unknown

BMP1

8:22058684:C:T

stopgain

1

19.09

1.84

NA

0.126

inherited

OFD1

X:13785314:C:T

stopgain

1

a

40.56

NA

0.884

inherited

TAZ

X:153649060:G:A

DNS

1

22.6

59.76

NA

NA

18:18629813:ATC:
frameshift 1
A

2:11587812:CTT:C frameshift 1

5:140720879:AGCC
frameshift 1
AG:A

7:98649018:CTG:C frameshift 1
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Table 4.6: Overview of candidate LVOTO genes detected by gene-based aggregation. This
table highlights 19 genes where cases present excess rare (MAF<1%) DNS alleles compared to
ARIC. Of note, DDX11 is implicated in human cardiovascular malformation and similar mouse
phenotypes, while the potential biological role for the remaining genes remains unclear. Sites =
number of DNS sites in this gene; p = T05 Burden test p-value; MAC = minor allele count;
CVM = cardiovascular malformation; MGI = mouse genome informatics.

Gene

p

beta

se

ZNF845
ABCD1
MAGEC1
KMT2C
OR4B1
GPX1
DHRS4L1
FMN2
CHIT1
UMODL1
AQP7
ABCB1
OR2T4
DDX11
NDUFV2
ZAN
FRG1B
KIAA1377
IL25

6.70E-60
4.86E-57
1.09E-55
8.78E-49
5.00E-33
2.11E-30
2.90E-27
3.20E-26
9.55E-24
7.01E-19
5.95E-18
2.87E-12
9.74E-12
1.36E-10
2.68E-08
8.20E-08
4.03E-07
8.15E-07
4.97E-06

4.76
3.14
4.27
1.96
3.48
5.02
2.44
2.22
2.83
2.23
2.34
1.8
3.76
1.32
3.05
1.28
1.1
2.85
2.48

0.29
0.2
0.27
0.13
0.29
0.44
0.23
0.21
0.28
0.25
0.27
0.26
0.55
0.21
0.55
0.24
0.22
0.58
0.54

DNS sites
3
18
8
149
11
5
9
26
18
26
21
39
6
50
9
43
19
7
4

MAC
case

MAC
control

Evidence

63
61
56
93
32
39
33
36
24
26
21
20
15
29
6
19
23
5
5

16
79
21
346
23
6
70
97
33
53
48
66
5
188
8
110
157
8
11

unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
CVM,MGI
unknown
unknown
unknown
unknown
unknown
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congenital heart defect candidate genes (Table 4.6). DDX11 encodes a DNA helicase which is
a cause of Warsaw breakage syndrome (MIM #613398), a human disorder which includes
ventral septal defects within its phenotypic spectrum. Additionally, mutation of this gene in
mouse models leads to developmental defects including abnormal heart looping90.

Clinical database supports novel LVOTO candidate genes
To identify additional CVM cases with similar underlying etiology, we surveyed an
additional 4,750 patients referred for clinical diagnostic testing for LOF variation in the LVOTO
discovery genes. Thirty individuals with LOF variation in LVOTO discovery genes also present
cardiovascular malformation, including severe left ventricular dysfunction (GRIP1) hypoplastic
left heart (KMT2D), heterotaxy syndrome (ARHGEF11) and more (Table 4.7). The overlapping
gene set also includes four genes ascertained by de novo mutations (JARID2, KMT2D, NF1,
SMURF1, ZEB2), bolstering support for these genes as contributors to congenital heart defects.
Discussion
Performing whole exome sequencing and analysis of a cohort of 342 unrelated LVOTO
cases, we detected 29 LOF variants among 28 genes with strong potential for involvement in
cardiac development. Our discovery gene set included six Mendelian genes previously
implicated in congenital heart malformation (DNAH5, KMT2D, OFD1, NF1, TBX20, ZEB2) and
16 genes associated with overlapping cardiac phenotypes in mammalian models (ACVR1,
BMP1, CDH2, FGF19, GJC1, GLRX3, JARID2, JMJD6, LATS2, LTBP1, NR2F2, OFD,
PCSK6, PLRG1, RAC1, and ROCK1) (Table 4.3). Among these are nine de novo mutations
which were verified through targeted parental sequencing.
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Table 4.7: Samples referred for clinical exome sequencing with cardiovascular malformation.
30 patients suspected of having a rare disorder (not necessarily including cardiovascular
symptoms) referred to the BCM/Miraca lab for clinical exome sequencing also presented
congenital heart disease and LOF mutations in our set of 28 discovery genes. TOF = Tetralogy
of Fallot; PDA = patent ductus arteriosis; ASD = atrial septal defects; VSD = ventral septal
defects; PFO = Patent foramen ovale.
Gene

Posn

Nucleotide

AminoAcid Zyg. Sex Age

CHD

ARHGEF11 1:156918388

c.29delA

p.E10fs

Het F 4y

Nonsyndromic cardiomyopathy
leading to heart transplantation

ARHGEF11 1:156909357

c.3958delT

p.Y1320fs

Het F 0m

Heterotaxy syndrome, right-sided and
dilated ascending aorta, TOF

CCDC91 12:28605463

c.978delA

p.R326fs

Het F 2y

ERRFI1

1:8075667

NM_018948

GRIP1

12:66747201

JARID2

6:15520368

c.2999T>A

KMT2D

12:49438290 c.4964-1_4978del

KMT2D

12:49427675

KMT2D

p.L1000X

PDA
Moderate secundum ASD, VSD,
moderate tricuspid valve
insufficiency, hypoplastic tricuspid
Het F 2y
valve, bicuspid aortic valve,
moderately hypoplastic right
ventricle, peripheral pulmonary artery
stenosis
Het M 10m Severe left ventricular dysfunction

c.3628_3629del p.1210_1210del Het M 9m

Aortic & pulmonic stenosis

N/A

Het F 1y

Mildly hypoplastic aortic arch, VSD,
pulmonary hypertension

c.10813C>T

p.Q3605X

Het F 14y

VSD, resolved

12:49426760

c.11728C>T

p.Q3910X

Het M 0m

Hypoplastic left heart

KMT2D

12:49425821

c.12667C>T

p.Q4223X

Het M 1m

KMT2D

12:49425644

c.12844C>T

p.R4282X

KMT2D

12:49420607

c.15142C>T

p.R5048C

KMT2D

12:49416416

c.16295G>A

p.R5432Q

Het M 2y

Bicuspid aortic valve

LATS2

13:21565531

c.355C>T

p.R119X

Het M 54y

Myocardial cyst

LATS2

13:21563131

c.786_787del

LGR4

11:27493693

c.156delC

Coarctation of the aorta
Shone's complex with small left sided
Het F 0m structures, mild coarctation, large
VSD
Shone syndrome, VSD, mitral valve
Het M 9y
stenosis, aortic arch hypoplasia

p.262_263del Het M 3y

Aortic root dilation

p.P52fs

Het F 7m

Distal abdominal aorta narrowing

LTBP1

2:33172449

c.59delC

p.S20fs

Het F 7m

Distal abdominal aorta narrowing

NF1

17:29496923

c.499_502del

p.C167fs

Het M 10y

TOF

OFD1

X:13785314

c.2668C>T

p.R890X

Hem M 1m

Situs inversus, possible VSD

p.V635fs

Het F 12y

PDA, PFO, cardiomegaly

PCSK6

15:101905203c.1903_1904insAG
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PCSK6

15:101853668 c.2569_2570del

RAC1

7:6438350

c.282+1G>A

SMAD7

18:46468987

c.41delA

SMURF1

7:98647229

c.988C>T

Cardiac arrest, ventricular fibrillation;
p.857_857del Het M 39y maternal history of sudden cardiac
death
Dilated aortic root & abnormal aortic
N/A
Het M 8y
valve
p.K14fs
Het F 10m
Dysplastic pulmonary valve
p.R330X

Het M 2y

Dextrocardia
Dysplastic pulmonic valve, small
ASD, small anterior muscular VSD,
Het F 3y
trivial mitral regurgitation, trivial
distal right PTAS
ASD, VSD, narrow aortic arch, leaky
Het M 9m
tricuspid valve

ZEB2

2:145161630 c.643_659del17

p.Y215fs

ZEB2

2:145157824 c.928_931delins8

p.Y310fs

ZEB2

2:145156682

c.2072G>A

p.W691X

Het M 4y

VSD, pulmonic valve stenosis

ZEB2

2:145156671

c.2083C>T

p.R695X

Het M 17y

Aortic stenosis

ZEB2

2:145154138

c.2908C>T

p.Q970X

Het M 1y

Pulmonary valve stenosis

ZEB2

2:145154011

c.3034delA

p.S1012fs

Het M 1y

Large flow PDA, secundum ASD,
muscular VSD, pulmonic stenosis
with dysplastic valve
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By focusing on case-exclusive LOF variation which intersected an a priori candidate
gene list, we identified contributing, if not causative, diagnosis for 7.9% (27/342) of our starting
cohort. Refining candidate gene selection may increase the number of discoveries within large
sample sets. Large-scale model organism knockout projects with deep phenotypes, such as the
Knockout Mouse Phenotyping Program (KOMP2), have great potential to facilitate the
identification of putative human disease genes. Similarly, functional expansion of variation to
include DNS variation facilitates disease gene discovery. This value is demonstrated by the
detection of excess DNS burden in DDX11, which identified risk alleles in an additional 26
(7.6%) LVOTO cases.
The results presented here offer insights into the complexity of the inheritance of
abnormal cardiac development. De novo mutations have been previously reported in CVM
cases79, and the role of this non-Mendelian-inherited variation is also supported by 9 genes in
the data reported here. In addition, it is well-established that up to 30% of parents of LVOTO
probands will have a similar, often more subtle, left-sided lesion, of the type that is only
apparent with imaging of the heart. Review of echocardiogram data for available parents of
affected probands showed that some of the transmitted damaging variants were inherited from
parents with milder LVOTO phenotypes (e.g. mild left sided lesions), whereas some were
inherited from parents without any evidence of current cardiac involvement.
This study implicates rare LOF and DNS along a broad spectrum of known and
postulated cardiac genes in the complex pathogenesis of LVOTO. These mutations may arise
de novo or be inherited from parents with milder but overlapping forms of CVM as well as in
apparently unaffected parents (perhaps reflecting incomplete penetrance)?. Our approach
illustrates the value of integrating an appropriately matched control group with model organism
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bioinformatics, which compliments a traditional family-based approach to assess inheritance
with the goal of identifying genes implicated in rare human disorders.
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Chapter 5: Synthesis and Discussion
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Genes and LOF trends
The previous chapters have described the analytical approaches and results of our studies
on the contribution on LOF variation to a broad spectrum of human traits, including common
chronic disease biomarkers, levels of small molecular metabolites, and rare congenital
cardiovascular malformation. Whole exome sequencing coupled with detailed annotation has
proved useful for discovery of novel gene candidates contributing to a broad phenotype
spectrum.
The function of certain genes during human development may be extremely sensitive to or
intolerant of gene dosage variation during viable human development, and large-scale
sequencing projects provide data to help identify these genes. Despite sequencing 8,554 ARIC
study participants, we did not observe any LOF variation in 11,380 genes (Figure 2.5).
Currently, the largest collection of publicly available exome sequence data (ExAC r0.3;
n~65000 individuals) describes at least one LOF allele in ~83% of human genes (17,005 out of
20,319 protein-coding Ensembl genes), suggesting that most human genes may tolerate some
level of LOF variation. As expected, many of the genes not tolerant to this variation represent
essential pathways to cellular function, such as ribosome formation, ubiquitination, and splicing
(Table 5.1). The prevalence of LOF variation will continue to be refined and characterized in
ongoing sequencing projects, and provide valuable insights into the robustness of the genome to
these mutations.
Metrics for gene tolerance to LOF variation will also be refined and informed by ongoing
studies, especially those informed by empirical LOF frequency in populations. The OP ratio
metric we developed in chapter 2 has already demonstrated potential for application towards
prioritizing novel gene contributing to human health. In chapter 2 we described a lower OP
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Table 5.1: Classification of genes intolerant to LOF variation. This table presents the top 8
KEGG pathways enriched for genes presenting no LOF alleles in ExAC. We identified 3,314
gene presenting no LOF alleles in the ExAC v0.3 database, and father selected 656 of these
which (1) encode for a known protein product and (2) have at least two exons, making them
eligible LOF candidates by our definition. This list of 656 genes was uploaded to the NIH
DAVID (http://david.abcc.ncifcrf.gov/) online bioinformatic resource for annotation and
pathway enrichment analysis.

KEGG pathway
Ribosome
Ubiquitin mediated proteolysis
Proteasome
TGF-beta signaling pathway
Chemokine signaling pathway
Spliceosome
Neurotrophin signaling pathway
Thyroid cancer

Genes
Count
32
13
7
8
13
10
9
4

%
5.9
2.4
1.3
1.5
2.4
1.8
1.7
0.7
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ratio in human paralogs of mouse embryonic lethal genes, and in chapter 4 we used this metric
to prioritize novel candidate genes for rare monogenic disease. Moving forward, the utility of
such a metric can be bolstered with refined LOF annotation methods.

Refining and expanding LOF annotation
Our annotation strategy was designed to enrich for exonic variation predicted to induce
EJC-mediated NMD degradation of mRNA transcripts. However, mRNA regulation is complex
and other mechanisms that influence gene dosage were not included in this study. For example,
the degradation of aberrant mRNA transcripts may be suppressed by miRNA silencing of
essential EJC-mediated NMD factors91. In addition, EJC-independent NMD of transcripts has
been reported, likely related to length of 3’ UTR92, which we did not consider in our analysis.
Expanding the genetic scope beyond protein-coding regions may capture additional
classes of LOF variation. For example, whole genome sequencing can be used to detect large
structural variants including large deletions that can span a significant portion of a reading
frame (especially the first exon) and may prevent protein formation24. In addition, certain
intergenic motifs are known to influence transcriptional efficiency. Mutations within gene
enhancer or silencer regions may influence gene expression levels93. Many of these loci are
described in the ENCODE project and these data are available to genome studies94. These
additional categories of variation affecting gene function may bolster the study of rare LOF
variation and human phenotypes, just as the inclusion of small frameshift indels in our analyses
complimented single nucleotide substitutions with a predicted LOF effect.
In addition to adding new classes, there are also potential to refine the selection and
annotation of more familiar categories of LOF variation. Recent mRNA sequencing studies
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provide opportunities to study the effect of genetic variation on mRNA transcripts. The GeneTissue Expression pilot project has performed RNAseq data on 43 tissue types from 175
individuals95, giving valuable insights into which transcript isoforms are expected in a given
tissue. The approach in these chapters was conservative, selecting predicted LOF variation
mapping to genomic regions used by all known isoforms for a given gene. However, an
alternative approach would be to restrict to variants mapping to isoforms expressed in tissues
known to influence the studied phenotype (ie, pancreas and insulin levels). It is important to
note that while a target-tissue approach may prevent the over-filtering of LOF sites from
analyses, it may limit the potential for discovery and the relevant tissue for a given phenotype
may not be known a priori.
In addition, recent studies suggest that LOF sites may be capable of allele-specific
expression (ASE) at a higher rate than non-LOF sites in coding regions96. At these loci, the
observed ratio of diploid transcript levels is not equal, with expression from one chromosome
dominating the other. These loci may confound the study of gene dosage, especially
heterozygous LOF variation, as these loci may effectively “escape” degradation of the
prematurely truncated transcript by upregulating the more functional transcript. Conservatively,
LOF variants mapping to these loci could be omitted from analyses, or a more quantitative
weight could be assigned based on the extent of allelic imbalance for a particular locus.

Applications & Future directions
Genes that influence human heath via dosage mutations have great potential to improve
healthcare. Specific applications may vary for each gene, especially whether LOF variation is
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associated with a protective or deleterious health effect, although some applications may apply
in either case.
Family history is already an important clinical component of assessing the risk for an
individual to develop certain diseases, and incorporating genetic variation is simply a refinement
of this predictive approach. Common population polymorphisms conveying modest risk are
already available to consumers through commercial genetic services, such as 23andMe
(www.23andme.com). In the clinic, rare mutations causing Mendelian disorders may be used to
assess risk within families with a history of disease, and can distinguish the individuals most
likely to develop disease97, but these sites may not be observed outside a few families. LOF
variation bridges the gap between these two extremes, in that the variation may be ascertained
more frequently than Mendelian mutations and the effects are larger than commonly applied
GWAS SNPs.
The potential for drug discovery with large deeply-phenotyped cohorts is enormous. LOF
studies identify genes in which the total transcript levels, rather than gene composition (amino
acid sequence) contribute to health. As such, the drugs which are developed as a result of
association studies may seek to influence overall gene levels, rather than mimic a specific amino
acid substitution as many synthetic forms of insulin act98. This presents opportunities for
multiple avenues (monoclonal antibodies, miRNA) of therapy. These drugs represent a
transition into a genomic era of medicine, where treatment options move beyond symptom
alleviation towards preventing the causes of disease before their onset.
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